tradingkey.logo
tradingkey.logo
Search

Otsuka Wins Japan Approval To Market Esperion’s Nexletol For Hypercholesterolemia Treatment

ReutersSep 19, 2025 12:31 PM
facebooktwitterlinkedin

- Esperion Therapeutics Inc ESPR.O:

  • ESPERION PARTNER OTSUKA RECEIVES REGULATORY APPROVAL TO MARKET NEXLETOL® IN JAPAN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

  • ESPERION THERAPEUTICS INC - ELIGIBLE FOR SALES MILESTONES AND ROYALTIES IN JAPAN

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI